Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Pediatric Data-Extrapolation Policies Questioned At Asthma Panel

Executive Summary

Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.

Advertisement

Related Content

Asthma Trials May Need More Pediatric Focus After GSK’s Mepolizumab, Breo Ellipta Woes
GSK’s Mepolizumab Panel Review May Hinge On Eosinophil Utility In Patient Selection
Breo Ellipta Stumbles On Pediatric Asthma Claim, But Advair Helps Break The Fall
Can GSK Market Breo Ellipta Dosing Advantage Without Adherence Advantage?
GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
Long Term Antipsychotic Use In Kids Okay With FDA, But Panel Has Concerns

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056750

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel